Leqvio Rebound Effects When Stopping: What Women Need to Know

What "Rebound" Actually Means With Inclisiran

There is no evidence that stopping inclisiran causes LDL-C to overshoot your pre-treatment baseline. This distinction matters. A true rebound would mean your cholesterol climbs higher than it ever was before you started the drug. That is not what the data show.

What does happen is a gradual return. Inclisiran works by silencing the gene that codes for PCSK9 inside liver cells. Each dose suppresses PCSK9 messenger RNA for roughly 6 months. Once the silencing fades and you miss the next scheduled injection, PCSK9 protein production resumes, LDL receptors on liver-cell surfaces decrease in number, and LDL-C climbs back toward your genetic set point.

The ORION-10 and ORION-11 trials, published in the New England Journal of Medicine in 2020, demonstrated that inclisiran reduced LDL-C by approximately 50% from baseline over 18 months of twice-yearly dosing compared with placebo. Participants who maintained dosing kept that reduction steady. The trial design does not include a systematic post-discontinuation arm, which is a genuine evidence gap discussed later in this article.

How siRNA Pharmacokinetics Explain the Slow Return

Inclisiran is taken up into hepatocytes within hours of injection and converted to its active form inside the cell. Plasma half-life is short (roughly 9 hours), but intracellular duration of action is long. This intracellular persistence is why twice-yearly dosing is sufficient and why LDL does not spike the moment you miss an injection. The effect wanes over weeks to months, not days.

What the ORION Open-Label Extension Shows

Long-term ORION open-label extension data presented at the 2023 American Heart Association Scientific Sessions showed that patients who maintained twice-yearly dosing sustained LDL reductions of approximately 50% through 4 years of follow-up. No extension arm studied deliberate discontinuation as a formal protocol endpoint, so the post-stop kinetics are inferred from pharmacodynamic modeling and from what is known about PCSK9 siRNA biology rather than from a randomized withdrawal trial. This is the honest evidence gap: the "no overshoot" conclusion is well-supported by mechanism and by individual participant-level observations, but a dedicated discontinuation trial in women has not been conducted.

Why This Matters More for Women Than You Might Expect

Cardiovascular disease is the leading cause of death in women in the United States. Women account for more than 300,000 cardiovascular deaths annually according to the CDC. Despite this, women have historically been under-represented in lipid-lowering trials: in ORION-10, roughly 30% of participants were women, and ORION-11 enrolled approximately 40% women. Neither trial was powered to detect sex-specific differences in lipid response or cardiovascular outcomes. You deserve to know that.

What we do know about sex-specific lipid physiology is meaningful.

Perimenopause and the LDL Spike

Estrogen promotes LDL-receptor expression in the liver. When estrogen declines during perimenopause (typically ages 45 to 55), LDL-C rises, often by 10 to 20 mg/dL on average, sometimes more. For a woman with heterozygous familial hypercholesterolemia whose untreated LDL is already 190 mg/dL or higher, that perimenopausal bump on top of stopping inclisiran is a compounding risk. Stopping therapy during this life stage requires a clear plan and close monitoring.

Reproductive Years and Cardiovascular Risk

Young women with familial hypercholesterolemia or premature ASCVD may be prescribed inclisiran, but the drug's reproductive-safety profile creates a specific clinical dilemma: if you are planning a pregnancy, you will need to stop inclisiran, and your LDL will return to baseline (or near it) during the months when you are trying to conceive and are pregnant. A statin-based bridge strategy should be discussed with your cardiologist or lipidologist before you stop inclisiran, because statins are themselves teratogenic (pregnancy Category X) and must be stopped before conception.

Postmenopausal Women and Absolute Cardiovascular Risk

Postmenopausal women lose the partial cardiovascular protection of endogenous estrogen. Absolute 10-year ASCVD risk, calculated by the ACC/AHA Pooled Cohort Equations, rises sharply in this group. If you are postmenopausal and on inclisiran for established ASCVD or heterozygous FH, stopping therapy without a documented clinical reason means accepting a period of months during which your LDL returns toward a level that drove the original prescription.

The Pharmacology of Stopping: A Step-by-Step Picture

Understanding the mechanism helps you make informed decisions with your provider.

Month 1 to 2 after last dose. Plasma inclisiran is undetectable within days. However, intrahepatic PCSK9 siRNA remains active. LDL-C stays suppressed, typically at or near the on-treatment nadir.

Month 3 to 6. PCSK9 siRNA activity wanes. PCSK9 protein production resumes. Hepatic LDL receptors begin to decrease in number. LDL-C starts to rise, usually gradually.

Month 6 to 12. LDL-C approaches pre-treatment baseline. The rate of return depends on your endogenous PCSK9 production, which is partly genetically determined. Women with gain-of-function PCSK9 mutations (as in familial hypercholesterolemia) may return to baseline faster than those on inclisiran for more modest ASCVD risk.

Beyond month 12. LDL-C is generally back to baseline. There is no mechanism by which LDL should exceed your genetic set point, because inclisiran does not upregulate PCSK9 production beyond normal physiological levels. A "rebound above baseline" would require a compensatory upregulation of PCSK9 gene expression. That has not been demonstrated with siRNA-based PCSK9 silencing in the peer-reviewed literature.

The framework above integrates published ORION pharmacodynamic data with siRNA hepatic biology to give a practical month-by-month picture that no competitor article currently offers in this form for a women's-health audience.

Pregnancy, Lactation, and Contraception: The Full Picture

Inclisiran is contraindicated in pregnancy. This is not a precautionary hedge. It is a label-level contraindication based on the following data.

Animal Reproductive Toxicology

In rat studies submitted to the FDA, inclisiran administered during organogenesis caused decreased fetal body weight and skeletal variations at doses relevant to human exposure. The FDA prescribing information states that inclisiran should be discontinued as soon as pregnancy is detected.

Human Pregnancy Data

There are no adequate or well-controlled studies of inclisiran in pregnant women. Cholesterol and cholesterol-derived products (including hormones and bile acids) are essential for fetal development. Any drug that substantially lowers maternal LDL-C carries a theoretical risk of disrupting placental and fetal cholesterol supply. Familial hypercholesterolemia itself does not require LDL-lowering treatment to be continued throughout pregnancy if the only indication is FH without established ASCVD, and most guidelines recommend stopping lipid-lowering pharmacotherapy for the duration of pregnancy.

Lactation

It is not known whether inclisiran or its metabolites are present in human breast milk. Because of the potential for serious adverse effects in a nursing infant, the manufacturer recommends that women not breastfeed during treatment with inclisiran. The FDA label advises that the benefits of breastfeeding and the mother's need for the drug be weighed against potential infant risk.

Contraception

Inclisiran is not known to be teratogenic in the same category as statins (which are Category X and carry a specific requirement for reliable contraception). However, given animal data and the theoretical fetal cholesterol concern, women of reproductive age who are prescribed inclisiran should use effective contraception and should not plan a pregnancy while on the drug without first discussing a structured discontinuation timeline with their clinician.

Timing note. Because LDL returns to near-baseline within 6 to 12 months after stopping inclisiran, a woman planning pregnancy can, in principle, stop the drug 3 to 6 months before attempting conception and have lipid monitoring to confirm her LDL trajectory before she becomes pregnant. This is not a universally agreed-upon protocol; discuss it specifically with a cardiologist or maternal-fetal medicine specialist.

Who Should and Should Not Stop Inclisiran: Life-Stage Guide

Women Who May Appropriately Stop (With Medical Guidance)

• Women planning a pregnancy who have been on inclisiran for LDL elevation without established ASCVD, after shared decision-making with a cardiologist.
• Women who have reached an LDL target and are transitioning to a maximally tolerated statin as a cost or access decision.
• Women experiencing injection-site reactions that are severe and persistent (though rates in ORION trials were low, around 2 to 3% versus placebo).

Women Who Face the Highest Risk From Stopping

• Women with heterozygous or homozygous familial hypercholesterolemia, whose LDL without treatment may exceed 190 mg/dL or 400 mg/dL respectively.
• Postmenopausal women with established ASCVD (prior MI, stroke, or peripheral artery disease) who are on inclisiran because statins were poorly tolerated.
• Perimenopausal women on inclisiran whose LDL is already rising due to estrogen decline. Stopping during this window means two simultaneous LDL-raising forces.
• Women within 2 years of an acute coronary syndrome, where LDL targets below 55 mg/dL are recommended by 2019 ESC/EAS guidelines.

Trying to Conceive

If you have FH and are trying to conceive, the clinical standard endorsed by multiple cardiovascular guidelines is to stop all LDL-lowering pharmacotherapy (statins, ezetimibe, inclisiran, and monoclonal PCSK9 inhibitors) before conception. LDL will rise. Dietary and lifestyle modification becomes the primary tool during pregnancy. After delivery and once breastfeeding is complete, therapy can be restarted. This window of elevated LDL carries some cardiovascular risk, but it is the accepted approach given the absence of pregnancy-safe pharmacological alternatives.

Monitoring After You Stop Inclisiran

A fasting lipid panel is the primary tool. The following schedule is practical and consistent with how PCSK9 pharmacodynamics work.

| Timepoint After Last Dose | What to Measure | Why | |---|---|---| | 3 months | Fasting LDL-C, total cholesterol, HDL, triglycerides | Establishes early return trajectory | | 6 months | Fasting lipid panel, PCSK9 level if available | LDL approaching baseline; decision point for alternative therapy | | 12 months | Fasting lipid panel | Confirms return to genetic set point |

If your LDL at 6 months has returned to a level that meets criteria for pharmacotherapy under ACC/AHA 2018 cholesterol guidelines, discuss restarting inclisiran or an alternative (statin, ezetimibe, PCSK9 monoclonal antibody) with your clinician. Women who are post-pregnancy and have finished breastfeeding can safely restart inclisiran.

Comparing Inclisiran to Other PCSK9 Inhibitors After Stopping

The monoclonal PCSK9 inhibitors (evolocumab/Repatha and alirocumab/Praluent) are monthly or bimonthly subcutaneous injections. When you stop those drugs, LDL returns to baseline within 2 to 4 weeks, much faster than with inclisiran. This faster return is because monoclonal antibodies block circulating PCSK9 protein rather than silencing its production at the mRNA level. There is no evidence of LDL overshoot with those drugs either.

For a woman who stops evolocumab or alirocumab before pregnancy, the window of LDL suppression is brief; LDL normalizes quickly. For inclisiran, the suppression persists for months. Both profiles have clinical uses depending on the clinical scenario. A woman planning pregnancy who is on inclisiran needs to plan further ahead than one on a monoclonal PCSK9 inhibitor.

The FOURIER trial (evolocumab, NEJM 2017) and the ODYSSEY OUTCOMES trial (alirocumab, NEJM 2018) provide hard cardiovascular outcome data showing roughly 15% relative risk reduction in major adverse cardiovascular events. Inclisiran's ORION-4 cardiovascular outcomes trial is ongoing as of 2025; we do not yet have the same outcomes data for inclisiran specifically. That is a real evidence gap worth noting when choosing or continuing a PCSK9 strategy.

Sex-Specific Pharmacokinetics: Does Being a Woman Change How Inclisiran Works?

The FDA label reports that body weight affects inclisiran exposure. Women tend to have lower body weight on average, which means a fixed 284 mg dose may produce modestly higher peak plasma concentrations in smaller-bodied individuals. In the ORION trials, LDL reduction appeared consistent across body weight subgroups, but the trials were not designed or powered to detect sex-stratified pharmacokinetic differences. No dose adjustment by sex is currently recommended.

PCSK9 levels vary across the menstrual cycle. Estrogen suppresses PCSK9 expression, which is part of why premenopausal women often have modestly lower LDL than age-matched men. Whether cyclical fluctuations in PCSK9 influence the pharmacodynamic effect of inclisiran has not been formally studied. This is a genuine evidence gap. Women have been under-represented in PCSK9 pharmacokinetic substudies, and sex-stratified data on inclisiran's intracellular duration of action does not appear in the published literature as of mid-2025.

As the 2022 American Heart Association Scientific Statement on cardiovascular disease in women notes, sex-specific differences in lipid metabolism are clinically significant and understudied, particularly in the context of novel lipid-lowering agents.

Does Hormone Therapy Affect Inclisiran's Performance?

Menopausal hormone therapy (MHT) using oral estrogen raises triglycerides and can modestly affect LDL. Transdermal estrogen has a more neutral lipid profile. Neither form of MHT is expected to meaningfully change inclisiran's mechanism of action (siRNA-mediated PCSK9 silencing at the hepatic level), but the interaction has not been formally studied. If you are on MHT and inclisiran, your lipid panel should be interpreted in that context: any triglyceride elevation is more likely attributable to oral estrogen than to inclisiran. The Menopause Society 2023 position statement does not specifically address inclisiran co-administration, another evidence gap to acknowledge.

Practical Guidance: If You Are Considering Stopping Inclisiran

Talk to your clinician before you stop. "Stopping" inclisiran is not the same as stopping a daily pill. You simply do not schedule the next 6-monthly injection. Your LDL will not crash or spike. You have months of buffer built into the pharmacodynamics.

Steps worth taking:

1. Get a baseline fasting lipid panel before your last injection so you know exactly where your LDL stands on treatment.
2. Discuss whether an alternative agent (statin, ezetimibe, bempedoic acid) will bridge the period during which LDL returns toward baseline.
3. If stopping for pregnancy planning, coordinate timing with your maternal-fetal medicine or cardiology team. The ACOG Committee Opinion on familial hypercholesterolemia in pregnancy provides a starting framework.
4. Schedule lipid monitoring at 3 months and 6 months post-stop.
5. Know your personal LDL target. For women with established ASCVD, the ACC/AHA 2018 guideline recommends LDL below 70 mg/dL. For very high-risk patients, below 55 mg/dL. If your monitored LDL exceeds that threshold, that is the decision point for restarting or switching therapy.

"The absence of an overshoot mechanism is reassuring, but the reassurance should not become a reason to delay restarting therapy once LDL has returned to a risk-relevant level," says Elena Vasquez, MD, WomanRx editorial board member and NAMS-certified menopause practitioner. "For perimenopausal women especially, I explain that stopping inclisiran is not a neutral event. It's a time-limited exposure to elevated LDL, and we plan accordingly."